Prostate cancer (PCa) is the leading cancer diagnosed and the second cause of cancer death in American men. Currently, therapeutic strategies for the treatment of hormone-independent metastatic PCa are very limited. The long-term goal of our competitive renewal application is to determine whether and how transforming growth factor beta (TGF2) signaling pathway can be targeted for the development of novel therapeutic approaches to inhibit PCa growth and metastasis in preclinical animal models. In our preliminary studies, we found that systemic administration of various TGF2 antagonists inhibited the growth and angiogenesis of xenograft prostate tumors and metastasis of orthotopic prostate tumors. The inhibition of prostate tumor progression by TGF2 antagonists was in part due to the blockade of TGF2 signaling in tumor-associated stromal cells because partial blockade of TGF2 signaling by the expression of a dominant-negative receptor in prostate stromal cells significantly attenuated their tumor-promoting activity. Thus, our central hypothesis in the competitive renewal application is that blockade of TGF2 signaling in prostate stromal cells may be developed as a novel strategy to inhibit PCa growth and metastasis. In our specific aim 1, we will employ a tumor and stromal cell co-transplantation system to determine the role of TGF2 signaling in prostate stromal cells in the regulation of tumor-stroma crosstalk and tumor progression. During the past funding cycle, we developed a novel TGF2-binding protein that can act as a pan-TGF2 antagonist. We have also developed a novel androgen-receptor positive human PCa cell line that induces osteoblastic bone metastasis when inoculated intracardiacally in mice. In our specific aim 2, we will compare the efficacy of the novel pan-TGF2 binding protein with that of a small TGF2 type I receptor kinase inhibitor in the inhibition of growth and metastasis of the novel PCa cell line as well as other PCa cells in xenograft and orthotopic PCa models and the spontaneous PCa model of TRAMP mice. In the specific aim 3, we will test the novel hypothesis that the combination of a TGF2 antagonist and a chemotherapeutic drug will produce a synergistic inhibitory effect on PCa growth and metastasis in xenograft and orthotopic PCa models. Our proposed research will reveal whether targeting TGF2 signaling in tumor-associated stromal cells is feasible as a novel therapeutic approach to inhibit PCa growth and metastasis in a preclinical setting. The knowledge gained from our research may lay the foundation for clinical trials with TGF2 antagonist alone or in combination with a chemotherapeutic agent for the treatment of metastatic PCa.

Public Health Relevance

Prostate cancer progression is associated with over-production of transforming growth factor beta (TGF2) and our preliminary studies have shown that TGF2 can drive hormone-independent prostate cancer progression and metastasis. Our proposed research will determine whether systemic treatment with TGF2 antagonists is of therapeutic potential for the inhibition of prostate tumor growth and bone metastasis in mouse models of prostate cancer. The knowledge gained from our research may lay the foundation for clinical trials with TGF2 antagonist alone or in combination with a chemotherapeutic agent for the treatment of metastatic PCa.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA079683-11
Application #
7835561
Study Section
Basic Mechanisms of Cancer Therapeutics Study Section (BMCT)
Program Officer
Muszynski, Karen
Project Start
1999-01-01
Project End
2013-03-31
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
11
Fiscal Year
2010
Total Cost
$221,767
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Biology
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Mukhopadhyay, Keya De; Liu, Zhao; Bandyopadhyay, Abhik et al. (2015) Aromatase expression increases the survival and malignancy of estrogen receptor positive breast cancer cells. PLoS One 10:e0121136
Biswas, Tanuka; Gu, Xiang; Yang, Junhua et al. (2014) Attenuation of TGF-? signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346:129-38
Mishra, Sweta; Lin, Chun-Lin; Huang, Tim H-M et al. (2014) MicroRNA-21 inhibits p57Kip2 expression in prostate cancer. Mol Cancer 13:212
Mishra, S; Deng, J J; Gowda, P S et al. (2014) Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene 33:4097-106
Wang, Danhan; Gao, Hui; Bandyopadhyay, Abhik et al. (2014) Pubertal bisphenol A exposure alters murine mammary stem cell function leading to early neoplasia in regenerated glands. Cancer Prev Res (Phila) 7:445-55
Gowda, Pramod S; Deng, Jianhong D; Mishra, Sweta et al. (2013) Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression. Mol Cancer Res 11:1448-61
Mu, Xiaoxin; Lin, Shu; Yang, Junhua et al. (2013) TGF-? signaling is often attenuated during hepatotumorigenesis, but is retained for the malignancy of hepatocellular carcinoma cells. PLoS One 8:e63436
Bandyopadhyay, Abhik; Dong, Qiaoxiang; Sun, Lu-Zhe (2012) Stem/progenitor cells in murine mammary gland: isolation and functional characterization. Methods Mol Biol 879:179-93
Liu, Zhao; Bandyopadhyay, Abhik; Nichols, Robert W et al. (2012) Blockade of Autocrine TGF-? Signaling Inhibits Stem Cell Phenotype, Survival, and Metastasis of Murine Breast Cancer Cells. J Stem Cell Res Ther 2:1-8
Lin, Shu; Yang, Junhua; Elkahloun, Abdel G et al. (2012) Attenuation of TGF-? signaling suppresses premature senescence in a p21-dependent manner and promotes oncogenic Ras-mediated metastatic transformation in human mammary epithelial cells. Mol Biol Cell 23:1569-81

Showing the most recent 10 out of 36 publications